Lexaria Bioscience Corp. – NASDAQ:LEXXW

Add to watchlist

$0.147

-0.65

-81.81%

Market closed

Open in 2 days

-20.20%

month

-20.20%

quarter

+101.50%

year

Market Cap	41.06M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.75

Revenue	318.71K
EBITDA	-5.70M
Income	-6.04M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-2054.12%
Oper. margin	-1785.45%
Gross margin	76.07%
EBIT margin	-1785.45%
EBITDA margin	-1789.59%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Lexaria Bioscience Corp. (NASDAQ:LEXXW): Profit margin
May 2023	93.15K	-2.37M	-2545.9%
Aug 2023	-3.43K	-1.23M	36100.17%
Feb 2024	145K	-649.53K	-447.96%
May 2024	84K	-1.78M	-2121.06%

Lexaria Bioscience Corp. (NASDAQ:LEXXW): Debt to assets
May 2023	5239637	1.19M	22.87%
Aug 2023	3083986	403.90K	13.1%
Feb 2024	6352043	204.20K	3.21%
May 2024	10018437	271.37K	2.71%

Lexaria Bioscience Corp. (NASDAQ:LEXXW): Cash Flow
May 2023	-1.78M	-33.64K	1.71M
Aug 2023	-1.62M	-68.43K	-121.68K
Feb 2024	-619.61K	-56.99K	3.45M
May 2024	-1.26M	-22.00K	5.04M

Lexaria Bioscience Corp. alternative data

Lexaria Bioscience Corp.
Employees

Lexaria Bioscience Corp. (NASDAQ:LEXXW): Employee count
Jan 2024	5
Feb 2024	5
Mar 2024	5
Apr 2024	5
May 2024	5
Jun 2024	5
Jul 2024	5

Lexaria Bioscience Corp.
Insider Trading

Lexaria Bioscience Corp. (NASDAQ:LEXXW): Insider trades (number of shares)
Period	Buy	Sel
Oct 2022	38621	0
Feb 2023	1500	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	9 Feb 2023	TURKEL CATHERINE C. director director	Common Shares	1,500	$2.85	$4,268
Purchase	14 Oct 2022	DOWNEY GREGORY officer: Chief Financial Officer officer: Chief Financial Officer	common shares	121	$2.09	$253
Purchase	13 Oct 2022	BUNKA CHRISTOPHER director, officer: Chief Executive Officer director, officer: Chief Execut..	common shares	16,600	$2.1	$34,860
Purchase	12 Oct 2022	BUNKA CHRISTOPHER director, officer: Chief Executive Officer director, officer: Chief Execut..	common shares	21,900	$1.99	$43,537
Purchase	10 Nov 2020	BUNKA CHRISTOPHER director, 10 percent owner, officer: CEO director, 10 percent owner, off..	common shares	25,500	$0.19	$4,794
Purchase	10 Nov 2020	BUNKA CHRISTOPHER director, 10 percent owner, officer: CEO director, 10 percent owner, off..	common shares	10,000	$0.2	$1,950
Purchase	10 Nov 2020	BUNKA CHRISTOPHER director, 10 percent owner, officer: CEO director, 10 percent owner, off..	common shares	6,000	$0.2	$1,200
Purchase	9 Nov 2020	BUNKA CHRISTOPHER director, 10 percent owner, officer: CEO director, 10 percent owner, off..	common shares	22,000	$0.2	$4,400
Purchase	9 Nov 2020	BUNKA CHRISTOPHER director, 10 percent owner, officer: CEO director, 10 percent owner, off..	common shares	10,000	$0.2	$2,030
Purchase	9 Nov 2020	BUNKA CHRISTOPHER director, 10 percent owner, officer: CEO director, 10 percent owner, off..	common shares	10,000	$0.21	$2,130

LEXXW insider trading transactions

Frequently Asked Questions (FAQ)

What's the price of Lexaria Bioscience Corp. stock today?

One share of Lexaria Bioscience Corp. stock can currently be purchased for approximately $0.15.
When is Lexaria Bioscience Corp.'s next earnings date?

Unfortunately, Lexaria Bioscience Corp.'s (LEXXW) next earnings date is currently unknown.
Does Lexaria Bioscience Corp. pay dividends?

No, Lexaria Bioscience Corp. does not pay dividends.
How much money does Lexaria Bioscience Corp. make?

Lexaria Bioscience Corp. has a market capitalization of 41.06M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 105.24% to 464.28K US dollars.
What is Lexaria Bioscience Corp.'s stock symbol?

Lexaria Bioscience Corp. is traded on the NASDAQ under the ticker symbol "LEXXW".
What is Lexaria Bioscience Corp.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Lexaria Bioscience Corp.?

Shares of Lexaria Bioscience Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Lexaria Bioscience Corp. have?

As Jul 2024, Lexaria Bioscience Corp. employs 5 workers.
What is Lexaria Bioscience Corp.'s official website?

The official website for Lexaria Bioscience Corp. is lexariabioscience.com.
How can i contact Lexaria Bioscience Corp.?

Lexaria Bioscience Corp. can be reached via phone at +250 7656424.

Lexaria Bioscience Corp.

lexariabioscience.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

+250 7656424

740 McCurdy Road
Kelowna, V1X 2P7

CIK: 0001348362
ISIN: US52886N1173
CUSIP: 52886N117